167 related articles for article (PubMed ID: 34584128)
61. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
62. Magnetic resonance imaging after external beam radiotherapy and concurrent chemotherapy for locally advanced cervical cancer helps to identify patients at risk of recurrence.
Angeles MA; Baissas P; Leblanc E; Lusque A; Ferron G; Ducassou A; Martínez-Gómez C; Querleu D; Martinez A
Int J Gynecol Cancer; 2019 Mar; 29(3):480-486. PubMed ID: 30712019
[TBL] [Abstract][Full Text] [Related]
63. Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation.
Wei Y; Wei C; Chen L; Liu N; Ou Q; Yin JC; Pang J; Fang Z; Wu X; Wang X; Mu D; Shao Y; Yu J; Yuan S
Cancer Res Treat; 2022 Oct; 54(4):1209-1218. PubMed ID: 35038823
[TBL] [Abstract][Full Text] [Related]
64. Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy.
Lin YC; Chen YC; Chen RY; Huang YX; Tu SJ; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY; Chen SW; Chang JG
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32527042
[TBL] [Abstract][Full Text] [Related]
65. Risk factors for pelvic and distant recurrence in locally advanced cervical cancer.
Queiroz ACM; Fabri V; Mantoan H; Sanches SM; Guimarães APG; Ribeiro ARG; da Nogueira Silveira Lima JP; Chen MJ; Baiocchi G; da Costa AABA
Eur J Obstet Gynecol Reprod Biol; 2019 Apr; 235():6-12. PubMed ID: 30771718
[TBL] [Abstract][Full Text] [Related]
66. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53.
Meulendijks D; Tomasoa NB; Dewit L; Smits PH; Bakker R; van Velthuysen ML; Rosenberg EH; Beijnen JH; Schellens JH; Cats A
Br J Cancer; 2015 Apr; 112(8):1358-66. PubMed ID: 25871546
[TBL] [Abstract][Full Text] [Related]
67. Prevalence of high-risk human papillomavirus infection among women in Shaanxi province of China: A hospital-based investigation.
Cao D; Zhang S; Zhang Q; Wei X; Zhao M; Ma Q; Li Y; Wang L; Pei M; Yang T; Zhao J; Yang X
J Med Virol; 2017 Jul; 89(7):1281-1286. PubMed ID: 27935120
[TBL] [Abstract][Full Text] [Related]
68. Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Wang J; Chai YL; Wang T; Liu JH; Dai PG; Liu Z
Exp Mol Pathol; 2015 Jun; 98(3):407-10. PubMed ID: 25773678
[TBL] [Abstract][Full Text] [Related]
69. Combined dynamic contrast enhanced MRI parameter with clinical factors predict the survival of concurrent chemo-radiotherapy in patients with 2018 FIGO IIICr stage cervical cancer.
Qin F; Pang H; Ma J; Zhao M; Jiang X; Tong R; Yu T; Luo Y; Dong Y
Eur J Radiol; 2021 Aug; 141():109787. PubMed ID: 34051683
[TBL] [Abstract][Full Text] [Related]
70. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Xu J; Xu S; Fang Y; Chen T; Xie X; Lu W
IUBMB Life; 2019 Mar; 71(3):347-356. PubMed ID: 30536701
[TBL] [Abstract][Full Text] [Related]
71. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.
Yokoi E; Mabuchi S; Takahashi R; Matsumoto Y; Kuroda H; Kozasa K; Kimura T
J Gynecol Oncol; 2017 Mar; 28(2):e19. PubMed ID: 28028992
[TBL] [Abstract][Full Text] [Related]
72. Increased High-Risk Human Papillomavirus Viral Load Is Associated With Immunosuppressed Microenvironment and Predicts a Worse Long-Term Survival in Cervical Cancer Patients.
Cao M; Wang Y; Wang D; Duan Y; Hong W; Zhang N; Shah W; Wang Y; Chen H
Am J Clin Pathol; 2020 Mar; 153(4):502-512. PubMed ID: 31819948
[TBL] [Abstract][Full Text] [Related]
73. Prevalence of high-risk human papillomavirus and cervical lesion risk factors: A population-based study in Zhejiang, China 2010-2019.
Lu W; Chen T; Yao Y; Chen P
J Med Virol; 2021 Aug; 93(8):5118-5125. PubMed ID: 33913528
[TBL] [Abstract][Full Text] [Related]
74. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Mayadev J; Nunes AT; Li M; Marcovitz M; Lanasa MC; Monk BJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1065-1070. PubMed ID: 32447296
[TBL] [Abstract][Full Text] [Related]
75. Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance.
Zhu B; Xiao Y; Yeager M; Clifford G; Wentzensen N; Cullen M; Boland JF; Bass S; Steinberg MK; Raine-Bennett T; Lee D; Burk RD; Pinheiro M; Song L; Dean M; Nelson CW; Burdett L; Yu K; Roberson D; Lorey T; Franceschi S; Castle PE; Walker J; Zuna R; Schiffman M; Mirabello L
Nat Commun; 2020 Feb; 11(1):886. PubMed ID: 32060290
[TBL] [Abstract][Full Text] [Related]
76. Prediction of disease progression following concurrent chemoradiotherapy for uterine cervical cancer: value of post-treatment diffusion-weighted imaging.
Park JJ; Kim CK; Park BK
Eur Radiol; 2016 Sep; 26(9):3272-9. PubMed ID: 26685853
[TBL] [Abstract][Full Text] [Related]
77. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.
Choi CH; Chung JY; Kang JH; Paik ES; Lee YY; Park W; Byeon SJ; Chung EJ; Kim BG; Hewitt SM; Bae DS
Gynecol Oncol; 2020 May; 157(2):437-443. PubMed ID: 32107047
[TBL] [Abstract][Full Text] [Related]
78. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy.
Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Sotoca A; Pérez-Ruiz E; Lanzós E
Am J Clin Oncol; 2011 Aug; 34(4):395-400. PubMed ID: 20859196
[TBL] [Abstract][Full Text] [Related]
79. Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE).
Yoshida K; Jastaniyah N; Sturdza A; Lindegaard J; Segedin B; Mahantshetty U; Rai B; Jürgenliemk-Schulz I; Haie-Meder C; Sasaki R; Pötter R
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):788-96. PubMed ID: 26530747
[TBL] [Abstract][Full Text] [Related]
80. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy.
Wen YF; Cheng TT; Chen XL; Huang WJ; Peng HH; Zhou TC; Lin XD; Zeng LS
PLoS One; 2018; 13(10):e0204334. PubMed ID: 30303986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
